Sturge-Weber Syndrome Companies | Market Research Future

Top Industry Leaders in the Sturge-Weber Syndrome Market

Sturge-Weber Syndrome Key Companies Disclaimer: List of key companies in no particular orderLatest Sturge-Weber Syndrome Companies Update

Oct 2023: Regarding an antibody medication it co-developed to avoid the respiratory syncytial virus (RSV), a major cause of infant hospitalizations, French pharmaceutical company Sanofi reported a "unprecedented level" of demand. The treatment, known as Beyfortus and created in collaboration with Sanofi and AstraZeneca, was approved in July to protect young children from RSV. Swedish Orphan Biovitrum's medicine Synagis was the only preventative therapy for high-risk newborns approved in the US before Sanofi's drug's approval. According to the American Academy of Pediatrics, 1% to 3% of children in the US under one year are admitted to hospitals because of RSV each year. According to Sanofi, it is collaborating with AstraZeneca to find more ways to satisfy the demand.

Jan 2023: The Switzerland-based company has obtained the CE mark for Aleva Neurotherapeutics' directSTIM Deep Brain Stimulation (DBS) system. By precisely guiding the current to the intended structural area, the DBS system technology increases DBS's efficacy and minimizes any negative consequences. It is claimed that Aleva Neurotherapeutics is the only technological company that has a CE mark for a DBS system. Through a post-market follow-up clinical study, it will start selling directly to certain neurological clinics in Europe. Our Deep Brain Stimulation System combines state-of-the-art directional electrode technology with a user-friendly patient programming interface to improve patient outcomes for functional neurosurgery teams.

List of Sturge-Weber Syndrome Key companies in the market